One injection could keep osteoarthritis drugs working for weeks
Researchers at the University at Buffalo have developed an injectable hydrogel that acts as a long-term drug reservoir for osteoarthritis treatment. The material transitions from a liquid to a semisolid at body temperature, allowing for sustained release of medication directly into the joint.
Why it matters
This innovation could significantly improve chronic pain management for osteoarthritis patients by reducing the frequency of injections and increasing treatment efficacy.
Scientists at the University at Buffalo have developed an injectable hydrogel designed to keep osteoarthritis treatments inside the joint for much longer than conventional injections.
After a single minimally invasive injection, the material changes from a liquid into a smooth, lubricating semisolid depot at body temperature. Once in place, it can remain in the joint for several weeks while gradually releasing drug-loaded nanocarriers.
A Major Challenge in Osteoarthritis Treatment
Osteoarthritis (OA) is one of the world's leading causes of chronic pain and disability. Common treatments delivered directly into joints, including analgesics, corticosteroids, and viscosupplements, can ease symptoms, but their effects are often short-lived, and they do not consistently slow the progression of the disease.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in